These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10409348)

  • 1. Genentech relaunched with independence intact.
    Glaser V
    Nat Biotechnol; 1999 Jul; 17(7):634. PubMed ID: 10409348
    [No Abstract]   [Full Text] [Related]  

  • 2. The art of mismanagement.
    Nat Biotechnol; 2006 Nov; 24(11):1300. PubMed ID: 17093455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 4. When the price is right.
    Nat Biotechnol; 2006 May; 24(5):473. PubMed ID: 16680108
    [No Abstract]   [Full Text] [Related]  

  • 5. Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
    McLean B
    Fortune; 2000 Jan; 141(1):132-4, 135. PubMed ID: 10788044
    [No Abstract]   [Full Text] [Related]  

  • 6. The socialite scientist.
    Serwer A
    Fortune; 2002 Apr; 145(8):152-4, 158, 160 passim. PubMed ID: 11961885
    [No Abstract]   [Full Text] [Related]  

  • 7. Promising drug is victim of bad business.
    Dove A
    Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
    [No Abstract]   [Full Text] [Related]  

  • 8. Just mad about mAbs.
    Jacobs T
    Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
    [No Abstract]   [Full Text] [Related]  

  • 9. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 10. Fresh from the biologic pipeline-2009.
    Sheridan C
    Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
    [No Abstract]   [Full Text] [Related]  

  • 11. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 12. HGS drug flop latest genomics setback.
    Reid B
    Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
    [No Abstract]   [Full Text] [Related]  

  • 13. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 14. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 15. Billion dollar babies--biotech drugs as blockbusters.
    Lawrence S
    Nat Biotechnol; 2007 Apr; 25(4):380-2. PubMed ID: 17420735
    [No Abstract]   [Full Text] [Related]  

  • 16. Patent threat in emerging economies shifts to biotech.
    Jayaranam K
    Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760
    [No Abstract]   [Full Text] [Related]  

  • 17. Biogen wins Euro MS approval, but loses patents.
    Brower V
    Nat Biotechnol; 1997 May; 15(5):410. PubMed ID: 9131611
    [No Abstract]   [Full Text] [Related]  

  • 18. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 19. Patenting race.
    Kahn J
    Nat Biotechnol; 2006 Nov; 24(11):1349-51. PubMed ID: 17093476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.